Albin Roger L, Frey Kirk A
Department of Neurology, Geriatric Research, Education, and Clinical Center, Ann Arbor VAMC, University of Michigan, Ann Arbor, USA.
Neurology. 2003 Feb 11;60(3):390-4. doi: 10.1212/01.wnl.0000052681.28286.52.
The evidence supporting initial dopamine agonist treatment of PD is reviewed. The two rationales for initial agonist treatment are reduced frequency of motor complications and possible relative neuroprotection by dopamine agonists. The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD.
本文综述了支持帕金森病（PD）初始多巴胺激动剂治疗的证据。初始激动剂治疗的两个理论依据是降低运动并发症的发生率以及多巴胺激动剂可能具有的相对神经保护作用。支持这些理论依据的基础科学证据并不明确。初始激动剂治疗优势的临床证据并不完整。需要更多数据来确定PD的最佳初始治疗方案。
